Nowadays the global industrial production of chondroitin sulfate (CS) has been based on uses of animal tissue sources as raw material, derived from different species of animals (porcine, bovine, avian and marine) including shark cartilage.
CS, like other natural polysaccharides, is derived from animal sources by extraction and purification processes. As a consequence, the source material, the manufacturing processes, the presence of contaminants and many other factors contribute to the quality, structure and physico-chemical properties of the final product and of the overall biological and pharmacological actions of these agents.
Moreover, during extractive procedures a mix of different animal tissues and sources is possible producing a final product having varied characteristics and not well identified profile, influencing oral absorption and activity.
Animal CS generally relies on bovine, porcine, chicken or cartilaginous fish such as sharks and skate by-products, in particular cartilage, as raw material. A mix of all these sources is possible producing a CS final product having mixed characteristics and low efficacy.
CS is extracted from cartilaginous feedstocks using organic solvents, with long purification processes that may cause chemical degradation/desulfation and loss of activity along with an uncontrolled and unreliable supply chain of CS raw materials.
The marine sourced Chondroitin often comes from sharks killed especially to fill the huge demand for this ingredient. These kind of sources could be unethical and often customers and market would not condone it.
Mythocondro® answers to the growing demand of effective prevention of the joint health in aging population and to the prerequisite of quality, safety and efficacy of a raw material of global manufacturers and consumers with a reliable and consistent solution.
Source material, manufacturing processes, the presence of contaminants, and many other factors contribute to the quality, structure and physico-chemical properties of the final product and of the overall biological and pharmacological actions of these agents.
The use of not controlled raw animal material (tissues, bones and cartilages) poses the problem of a final product having a highly variable structure with not well identified origin and poor reproducibility with the consequence of variable grade of purity, biological effects, presence of contaminants, clinical efficacy and safety.
Extraction and purification processes may introduce further modifications of the structural characteristics and properties of Chondroitin Sulfate preparations.